Literature DB >> 16784182

Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty.

Marianne Yngen1, Anna Norhammar, Paul Hjemdahl, N Håkan Wallén.   

Abstract

The aim of this study was to investigate the impact of improved metabolic control on platelet reactivity in patients with type 2 diabetes undergoing percutaneous coronary intervention (PCI). Twenty-two patients were randomised to intensive insulin or conventional treatment for diabetes. Platelet P-selectin expression was analysed before and three months after PCI. Metabolic control, as measured by level of glycosylated haemoglobin (HbA1c) and platelet P-selectin expression, was similar in the two treatment groups after three months. However, six of the 12 patients in the intensive group had increased levels of HbA1c after three months and three patients of the 10 in the conventionally treated group showed improved metabolic control. A re-analysis was performed, based on metabolic control. It showed that patients with improved control at three months (HbA1c 6.1% +/- 0.7 at baseline; 5.7% +/- 0.5 at three months; p<0.01; n=9) had lower ADP-induced P-selectin expression (p<0.05) than patients with worsened glycaemic control (HbA1c 5.9% +/- 1.0 at baseline; 6.5% +/- 1.4 at three months; p<0.01; n=13). Levels of HbA1c and fasting glucose were correlated to P-selectin expression (R=0.34 and R=0.31; p<0.05). We conclude from this study that improved glycaemic control reduces platelet reactivity in type 2 diabetes patients following PCI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784182     DOI: 10.3132/dvdr.2006.008

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  12 in total

Review 1.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

2.  The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.

Authors:  Thomas Schöndorf; Petra B Musholt; Cloth Hohberg; Thomas Forst; Ute Lehmann; Winfried Fuchs; Mirjam Löbig; Jürgen Müller; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2011-03-01

3.  Factors contributing to increased platelet reactivity in people with diabetes.

Authors:  David J Schneider
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

4.  Glycemic Control in Coronary Revascularization.

Authors:  Francisco Ujueta; Ephraim N Weiss; Steven P Sedlis; Binita Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

5.  The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.

Authors:  Naveen Seecheran; Arvinash Ramdeen; Niranjan Debideen; Kabeer Ali; Kathryn Grimaldos; Gabriella Grimaldos; Abhinav Karan; Rajeev Seecheran; Valmiki Seecheran; Sangeeta Persad; Harun Abdullah; Lakshmipathi Peram; Stanley Giddings; Shastri Motilal; Antonio Tello-Montoliu; David Schneider
Journal:  Cardiol Ther       Date:  2020-12-11

6.  Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective.

Authors:  Nicholaos Kakouros; Jeffrey J Rade; Antonios Kourliouros; Jon R Resar
Journal:  Int J Endocrinol       Date:  2011-08-21       Impact factor: 3.257

Review 7.  Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Bianca Hemmingsen; Søren S Lund; Christian Gluud; Allan Vaag; Thomas Almdal; Christina Hemmingsen; Jørn Wetterslev
Journal:  BMJ       Date:  2011-11-24

8.  High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.

Authors:  Gadi Shlomai; Tal Haran-Appel; Tal Sella; Yoni Grossman; Hagit Hauschner; Nurit Rosenberg; Ehud Grossman
Journal:  Cardiovasc Diabetol       Date:  2015-06-12       Impact factor: 9.951

9.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

10.  Mean platelet volume in Type 2 diabetes mellitus.

Authors:  Thomas Alex Kodiatte; Udaya Kumar Manikyam; Suraksha Bellur Rao; Thej Mothakapalli Jagadish; Madhavi Reddy; Harendra Kumar Malligere Lingaiah; Venkataswamy Lakshmaiah
Journal:  J Lab Physicians       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.